Transcept Pharmaceuticals (TSPT) jumps in the post-session after the company announces its will...

|By:, SA News Editor

Transcept Pharmaceuticals (TSPT) jumps in the post-session after the company announces its will resubmit its New Drug Application to the FDA seeking its approval of Intermezzo. Earlier today the FDA had notified the company that it generally agreed with its new proposals following the drug's rejection in July. Shares +13.7% AH.